Drugs / TCR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02686372 | May 2018 → Sep 2021 | hepatocellular carcinoma | Lion TCR Pte. Ltd. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-14 | Lion TCR Pte. Ltd. | Lion TCR Secures China NMPA IND Approval for GZL-016, an Innovative mRNA-based TCR-T Cell Therapy for Hepatocellular Carcinoma liontcr.com ↗ |
| 2023-07-04 | Lion TCR Pte. Ltd. | Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy liontcr.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02686372 ↗ |
| Modality | Cell therapy | “Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR” NCT02686372 ↗ |